Evidence map›Paper›PMID 33710538›Full record

ArticleNeurochemical research2021

DHCR24 Knockdown Lead to Hyperphosphorylation of Tau at Thr181, Thr231, Ser262, Ser396, and Ser422 Sites by Membrane Lipid-Raft Dependent PP2A Signaling in SH-SY5Y Cells.

Zihan Qi, Ying Zhang, Kai Yao, Mengqi Zhang, Yixuan Xu, Jianfeng Zhang, Xiaojing Bai, Hengbing Zu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Neuroprotection and Mechanism of Gas-miR36-5p fromInternational journal of molecular sciences · 2023
    Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Zihan Qi *Department of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Ying ZhangDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Kai YaoDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Mengqi ZhangDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Yixuan XuDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Jianfeng ZhangDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Xiaojing BaiDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China. 16211270015@fudan.edu.cn.
Hengbing ZuDepartment of Neurology, Jinshan Hospital, Fudan University, Shanghai, 201508, China. hbzyy666@163.com.ORCID http://orcid.org/0000-0002-0150-744X
Jinshan Hospital of Fudan University · CN

Funding

201740209 from the Shanghai Health and Medical Development Foundation 201740209JSZK2015A05 from the Shanghai Jinshan District Key Medical Foundation JSZK2015A05
6 · The paper itself

Abstract

Accumulating data suggest that the downregulation of DHCR24 is linked to the pathological risk factors of AD, denoting a potential role of DHCR24 in AD pathogenesis. However, it remains unclear whether the downregulation of DHCR24 affects the abnormal heper-phosphorylation of tau protein, which is involved in tauopathy. In present papers, immunofluorescence and Filipin III fluorescence results showed that DHCR24 knockdown significantly lowered the level of plasma membrane cholesterol and expression level of membrane lipid-raft structural protein caveolin-1; and overexpression of DHCR24 could increase the plasma membrane cholesterol levels and facilitating caveolae structure through increase the expression of caveolin-1. PP2A is the key phosphatase involving in tau phosphorylation, which is localized in cholesterol-dependent caveola/raft lipid domains. Here, the PP2A activity was detected by western blot assay. Interestingly, the level of p-PP2Ac at Y307 (inactive) and p-GSK3β at Y216 (active) in the downstream of the PP2A signal pathway were both significantly increased in silencing DHCR24 SH-SY5Y cells, which denoted an inhibition of the PP2A and activation of GSK3β signaling. Conversely, overexpression of DHCR24 blunted the inhibition effect of PP2A and activation of GSK3β. Besides, in the SH-SY5Y cell lines we demonstrated that DHCR24 knockdown obviously induced hyperphosphorylation of tau at Thr181, Thr231, Ser262, Ser396, and Ser422 Sites. In contrast, DHCR24 overexpression protects neuronal SH-SY5Y cells against the hyperphosphorylation of tau at Thr181, Thr231, Ser262, Ser396, and Ser422 Sites. Furthermore, PP2A activator D-erythro-Sphingosine (DES) also obviously inhibited the hyperphosphorylation of tau induced by DHCR24 knockdown. Collectively, our findings firstly confirmed that DHCR24 knockdown obviously induced abnormal hyperphosphorylation of tau by a novel lipid raft-dependent PP2A signaling. We propose that DHCR24 downregulation led to altered cholesterol synthesis as a potential mechanism in the progression of tau hyperphosphorylation involving in AD and other tauopathies.

Indexed as

Caveolin 1Cell Line, TumorCell ProliferationCholesterolGene Knockout TechniquesGlycogen Synthase Kinase 3 betaHumansMembrane MicrodomainsNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsPhosphorylationProtein Phosphatase 2SerineSignal Transductiontau ProteinsThreonineCAV1 protein, humanCaveolin 1CholesterolDHCR24 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanNerve Tissue ProteinsOxidoreductases Acting on CH-CH Group DonorsProtein Phosphatase 2Serinetau ProteinsThreonineAlzheimer’s diseaseDHCR24HyperphosphorylationPP2ATauTauopathy

Identifiers

PMID33710538
OpenAlexW3133938820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.